EMA — authorised 31 December 2009
- Application: EMEA/H/C/000653
- Marketing authorisation holder: CIS bio international
- Local brand name: Scintimun
- Status: withdrawn
🇪🇺 Scintimun in European Union
EMA authorised Scintimun on 31 December 2009
Marketing authorisations
EMA — authorised 11 January 2010
- Marketing authorisation holder: CIS bio international
- Status: approved
EMA — authorised 11 January 2010
- Application: EMEA/H/C/001045
- Marketing authorisation holder: Telix Innovations
- Local brand name: Scintimun
- Indication: This medicinal product is for diagnostic use only and the approved indication is scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. Scintimun should not be used for the diagnosis of diabetic foot infection.
- Status: approved
Scintimun in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in European Union
Frequently asked questions
Is Scintimun approved in European Union?
Yes. EMA authorised it on 31 December 2009; EMA authorised it on 11 January 2010; EMA authorised it on 11 January 2010.
Who is the marketing authorisation holder for Scintimun in European Union?
CIS bio international holds the EU marketing authorisation.